---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-040769"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2022-07-22T23:59:59+00:00"
generated_at: "2026-06-24T09:40:45.518767+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Larkspur Health Acquisition Corp. announces business combination with ZyVersa Therapeutics and $7M private placement

## Summary
- SPAC Larkspur (LSPR) entered into Business Combination Agreement with ZyVersa Therapeutics, a clinical-stage biopharma targeting renal and inflammatory diseases.
- Private placement of approximately $7.0M in Convertible Preferred shares and warrants to fund the deal, subject to additional interim financing and Nasdaq listing.
- Closing deadline set for December 15, 2022; transaction requires shareholder approval and other customary conditions.
- ZyVersa will survive as a wholly owned subsidiary; combined company expected to be named ZyVersa Therapeutics.
- Company warrants and options assumed and converted into SPAC equity; key shareholders enter lock-up and support agreements.

## SEC filing metadata
- accession: 0001213900-22-040769
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2022-07-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000121390022040769/0001213900-22-040769-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000121390022040769/ea163113-8k425_larkspur.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-040769
- JSON: https://secwatch.observer/filing/0001213900-22-040769.json
- Plain text: https://secwatch.observer/filing/0001213900-22-040769.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.